» Articles » PMID: 15957152

Pleomorphic Lobular Carcinoma of the Breast: Role of Comprehensive Molecular Pathology in Characterization of an Entity

Overview
Journal J Pathol
Specialty Pathology
Date 2005 Jun 16
PMID 15957152
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Immunohistochemical analysis of E-cadherin has changed the way lobular neoplasia is perceived. It has helped to classify difficult cases of carcinoma in situ with indeterminate features and led to the identification of new variants of lobular carcinoma. Pleomorphic lobular carcinoma (PLC) and pleomorphic lobular carcinoma in situ (PLCIS), recently described variants of invasive and in situ classic lobular carcinoma, are reported to be associated with more aggressive clinical behaviour. Although PLC/PLCIS show morphological features of classic lobular neoplasia and lack E-cadherin expression, it is still unclear whether these lesions evolve through the same genetic pathway as lobular carcinomas or are high-grade ductal neoplasms that have lost E-cadherin. Here we have analysed a case of extensive PLCIS and invasive PLC associated with areas of E-cadherin-negative carcinoma in situ with indeterminate features, using immunohistochemistry, chromogenic in situ hybridization, high-resolution comparative genomic hybridization (CGH) and array-based CGH. We observed that all lesions lacked E-cadherin and beta-catenin and showed gain of 1q and loss of 16q, features that are typical of lobular carcinomas but are not seen in high-grade ductal lesions. In addition, amplifications of c-myc and HER2 were detected in the pleomorphic components, which may account for the high-grade features in this case and the reported aggressive clinical behaviour of these lesions. Taken together, these data suggest that at least some PLCs may evolve from the same precursor or through the same genetic pathway as classic lobular carcinomas.

Citing Articles

Surgery for Classic, Pleomorphic and Non-classic Lobular Carcinoma In Situ: Surgery Rate, Risk of Upstaging and Short-Term Follow-Up.

Meurs C, Kerkhoven C, Siesling S, Menke-Pluijmers M, Westenend P Ann Surg Oncol. 2024; 32(4):2545-2553.

PMID: 39738900 DOI: 10.1245/s10434-024-16686-8.


Nuclear morphological characterisation of lobular carcinoma variants: a morphometric study.

Katayama A, Makhlouf S, Toss M, Oyama T, Rakha E Histopathology. 2024; 86(5):813-823.

PMID: 39654376 PMC: 11903112. DOI: 10.1111/his.15390.


Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses.

Zhang Y, Luo X, Chen M, Yang L, Lei T, Pu T Breast Cancer Res Treat. 2022; 194(2):279-295.

PMID: 35666367 DOI: 10.1007/s10549-022-06627-y.


Targetable alterations in invasive pleomorphic lobular carcinoma of the breast.

Riedlinger G, Joshi S, Hirshfield K, Barnard N, Ganesan S Breast Cancer Res. 2021; 23(1):7.

PMID: 33441174 PMC: 7805167. DOI: 10.1186/s13058-020-01385-5.


Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma.

Segar J, Pandey R, Farr K, Nagle R, LeBeau L, Gonzalez V Int J Breast Cancer. 2020; 2020:8816824.

PMID: 33299611 PMC: 7704199. DOI: 10.1155/2020/8816824.